Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Werewolf Therapeutics (HOWL) Invested Capital (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Invested Capital for 5 consecutive years, with $29.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 66.87% to $29.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $29.6 million, a 66.87% decrease, with the full-year FY2024 number at $73.4 million, down 34.1% from a year prior.
  • Invested Capital was $29.6 million for Q3 2025 at Werewolf Therapeutics, down from $41.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $181.6 million in Q2 2021 to a low of -$153.8 million in Q1 2021.
  • A 5-year average of $97.3 million and a median of $117.6 million in 2024 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: skyrocketed 190.61% in 2022, then crashed 66.87% in 2025.
  • Werewolf Therapeutics' Invested Capital stood at $152.8 million in 2021, then decreased by 19.93% to $122.3 million in 2022, then dropped by 8.96% to $111.4 million in 2023, then tumbled by 34.1% to $73.4 million in 2024, then crashed by 59.65% to $29.6 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Invested Capital are $29.6 million (Q3 2025), $41.5 million (Q2 2025), and $57.3 million (Q1 2025).